S&P 500   3,221.96 (+0.76%)
DOW   26,808.05 (+0.62%)
QQQ   260.47 (+0.03%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,221.96 (+0.76%)
DOW   26,808.05 (+0.62%)
QQQ   260.47 (+0.03%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,221.96 (+0.76%)
DOW   26,808.05 (+0.62%)
QQQ   260.47 (+0.03%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,221.96 (+0.76%)
DOW   26,808.05 (+0.62%)
QQQ   260.47 (+0.03%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
Log in

NASDAQ:PTGXProtagonist Therapeutics Earnings Date, Estimates & History

$16.80
+1.21 (+7.76 %)
(As of 07/15/2020 02:53 PM ET)
Add
Compare
Today's Range
$16.24
Now: $16.80
$16.99
50-Day Range
$15.19
MA: $16.92
$18.64
52-Week Range
$4.47
Now: $16.80
$19.67
Volume169,157 shs
Average Volume608,209 shs
Market Capitalization$460.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41

Earnings

Protagonist Therapeutics (NASDAQ:PTGX) Earnings Information

Protagonist Therapeutics last posted its quarterly earnings data on May 7th, 2020. The reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.03. The company had revenue of $3.65 million for the quarter, compared to analysts' expectations of $3.60 million. Protagonist Therapeutics has generated ($2.98) earnings per share over the last year. Protagonist Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 5th, 2020 based off prior year's report dates.

Protagonist Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Protagonist Therapeutics (NASDAQ:PTGX) Earnings Estimates

2020 EPS Consensus Estimate: ($2.03)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20201($0.53)($0.53)($0.53)
Q2 20201($0.50)($0.50)($0.50)
Q3 20201($0.50)($0.50)($0.50)
Q4 20201($0.50)($0.50)($0.50)

Protagonist Therapeutics (NASDAQ PTGX) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
8/5/2020
(Estimated)
       
5/7/20203/31/2020($0.69)($0.72)($0.72)$3.60 million$3.65 millionTranscript
3/10/202012/31/2019($0.65)($0.63)($0.63)$5.25 million$2.72 millionTranscript
11/6/2019Q3($0.71)($0.61)($0.61)$5.75 million$4.14 millionN/A
8/7/2019Q2 2019($0.28)($1.1829)($1.18)$10.77 million($8.19) millionN/A
5/8/20193/31/2019($0.59)($0.58)($0.58)$2.50 million$1.56 millionN/A
3/12/201912/31/2018($0.42)($0.57)($0.57)$5.45 million$2.35 millionTranscript
11/6/2018Q3($0.3730)($0.38)($0.38)$6.35 million$6.12 millionN/A
8/7/2018Q2 2018($0.3420)($0.41)($0.41)$8.55 million$11.67 millionN/A
5/9/2018Q1 2018($0.29)($0.36)($0.36)$10.70 million$10.78 millionN/A
3/7/2018Q4 2017($0.3420)($0.15)($0.15)$8.75 million$11.28 millionN/A
11/6/2017Q3 2017($0.6920)($0.29)($0.29)$8.78 millionN/A
8/8/2017Q2 2017($0.1870)($0.89)($0.89)N/A
5/10/2017Q1 2017($0.61)($0.84)($0.84)N/A
3/7/2017Q4 2016($0.49)($0.67)($0.67)N/A
11/14/2016Q3 2016($0.49)($0.87)($0.87)N/A
9/15/2016Q2 2016($1.07)($19.07)($19.07)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.